Strong Commercial Performance
The quarter's commercial performance was strong across the portfolio, particularly in Europe, emerging markets, and Greater China, with 1% operational revenue growth excluding Indore.
R&D Advancements
Progress was made in the R&D pipeline, including advancements in the fast-acting meloxicam, sotagliflozin filings in multiple markets, and Phase III enrollment for selatogrel and cenerimod.
Capital Return to Shareholders
Over $920 million returned to shareholders year-to-date, including $500 million in share repurchases, on track to return over $1 billion in capital for the year.
Positive New Product Revenue Momentum
New product revenues in Europe grew by 5%, driven by new products in key markets like France and Italy.